Počet záznamů: 1  

Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer's Disease

  1. 1.
    0525539 - ÚOCHB 2021 RIV US eng J - Článek v odborném periodiku
    Šála, Michal - Hollinger, K. R. - Thomas, A. G. - Dash, R. P. - Tallon, C. - Veeravalli, V. - Lovell, L. - Kögler, Martin - Hřebabecký, Hubert - Procházková, Eliška - Nešuta, Ondřej - Donoghue, A. - Lam, J. - Rais, R. - Rojas, C. - Slusher, B. S. - Nencka, Radim
    Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer's Disease.
    Journal of Medicinal Chemistry. Roč. 63, č. 11 (2020), s. 6028-6056. ISSN 0022-2623. E-ISSN 1520-4804
    Grant CEP: GA MŠMT(CZ) EF16_019/0000729
    Institucionální podpora: RVO:61388963
    Klíčová slova: cognitive impairment * in vivo * metabolism
    Obor OECD: Organic chemistry
    Impakt faktor: 7.446, rok: 2020
    Způsob publikování: Omezený přístup
    https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00278

    Neutral sphingomyelinase 2 (nSMase2) catalyzes the cleavage of sphingomyelin to phosphorylcholine and ceramide, an essential step in the formation and release of exosomes from cells that is critical for intracellular communication. Chronic increase of brain nSMase2 activity and related exosome release have been implicated in various pathological processes, including the progression of Alzheimer’s disease (AD), making nSMase2 a viable therapeutic target. Recently, we identified phenyl (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)carbamate 1 (PDDC), the first nSMase2 inhibitor that possesses both favorable pharmacodynamics and pharmacokinetic (PK) parameters, including substantial oral bioavailability, brain penetration, and significant inhibition of exosome release from the brain in vivo. Herein we demonstrate the efficacy of 1 (PDDC) in a mouse model of AD and detail extensive structure–activity relationship (SAR) studies with 70 analogues, unveiling several that exert similar or higher activity against nSMase2 with favorable pharmacokinetic properties.
    Trvalý link: http://hdl.handle.net/11104/0309645

     
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.